{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:58:55Z","timestamp":1774468735428,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01221-2","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:11:05Z","timestamp":1773256265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of a Modified In Situ Perfusion Model to Quantify Intestinal Drug Excretion and Transporter-Mediated Interactions after Intravenous Administration"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-4501","authenticated-orcid":false,"given":"Rongjin","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2280-3755","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-6790","authenticated-orcid":false,"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3977-4006","authenticated-orcid":false,"given":"Zuoxu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2161-5664","authenticated-orcid":false,"given":"Dinh","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2562-3453","authenticated-orcid":false,"given":"Zicong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-7416","authenticated-orcid":false,"given":"Xiaofeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2210-3432","authenticated-orcid":false,"given":"Jia","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0026-0887","authenticated-orcid":false,"given":"John","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0826-4680","authenticated-orcid":false,"given":"Taijun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3009-9435","authenticated-orcid":false,"given":"Yiding","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-333X","authenticated-orcid":false,"given":"Yurong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-6294","authenticated-orcid":false,"given":"Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"2","key":"1221_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1203\/00006450-199708000-00011","volume":"42","author":"P Kotal","year":"1997","unstructured":"Kotal P, Van der Veere CN, Sinaasappel M, Elferink RO, Vitek L, Brodanova M, et al. Intestinal excretion of unconjugated bilirubin in man and rats with inherited unconjugated hyperbilirubinemia. Pediatr Res. 1997;42(2):195\u2013200.","journal-title":"Pediatr Res"},{"issue":"3","key":"1221_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1053\/j.gastro.2007.06.019","volume":"133","author":"AE van der Velde","year":"2007","unstructured":"van der Velde AE, Vrins CL, van den Oever K, Kunne C, Oude Elferink RP, Kuipers F, et al. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology. 2007;133(3):967\u201375.","journal-title":"Gastroenterology"},{"issue":"3","key":"1221_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1023\/A:1011959828103","volume":"15","author":"K Arimori","year":"1998","unstructured":"Arimori K, Nakano M. Drug exsorption from blood into the gastrointestinal tract. Pharm Res. 1998;15(3):371\u20136.","journal-title":"Pharm Res"},{"issue":"6","key":"1221_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1124\/dmd.30.6.626","volume":"30","author":"CM Laffont","year":"2002","unstructured":"Laffont CM, Toutain PL, Alvinerie M, Bousquet-Melou A. Intestinal secretion is a major route for parent ivermectin elimination in the rat. Drug Metab Dispos. 2002;30(6):626\u201330.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1221_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0009-9236(96)90182-4","volume":"59","author":"T Gramatte","year":"1996","unstructured":"Gramatte T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther. 1996;59(5):541\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1221_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0009-9236(99)70031-7","volume":"66","author":"T Gramatte","year":"1999","unstructured":"Gramatte T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther. 1999;66(3):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1221_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1067\/mcp.2003.27","volume":"73","author":"S Drescher","year":"2003","unstructured":"Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003;73(3):223\u201331.","journal-title":"Clin Pharmacol Ther"},{"key":"1221_CR8","unstructured":"U.S. Food and Drug Administration. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system: guidance for industry. Silver Spring (MD): Center for Drug Evaluation and Research; 2017. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070246.pdf. Accessed January 13, 2026."},{"issue":"8","key":"1221_CR9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1124\/dmd.116.070532","volume":"44","author":"K Kato","year":"2016","unstructured":"Kato K, Hasegawa Y, Iwata K, Ichikawa T, Yahara T, Tsuji S, et al. Recommendation to exclude bile-duct-cannulated rats with hyperbilirubinemia for proper conduct of biliary drug excretion studies. Drug Metab Dispos. 2016;44(8):1180\u20133.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1221_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.drudis.2013.11.020","volume":"19","author":"Y Gao","year":"2014","unstructured":"Gao Y, Shao J, Jiang Z, Chen J, Gu S, Yu S, et al. Drug enterohepatic circulation and disposition: constituents of systems pharmacokinetics. Drug Discov Today. 2014;19(3):326\u201340.","journal-title":"Drug Discov Today"},{"issue":"2","key":"1221_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ijpharm.2014.11.035","volume":"478","author":"J Stappaerts","year":"2015","unstructured":"Stappaerts J, Brouwers J, Annaert P, Augustijns P. In situ perfusion in rodents to explore intestinal drug absorption: challenges and opportunities. Int J Pharm. 2015;478(2):665\u201381.","journal-title":"Int J Pharm"},{"issue":"10","key":"1221_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1023\/A:1015927004752","volume":"5","author":"GL Amidon","year":"1988","unstructured":"Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res. 1988;5(10):651\u20134.","journal-title":"Pharm Res"},{"issue":"10-11","key":"1221_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/00498250701704819","volume":"37","author":"H Lennernas","year":"2007","unstructured":"Lennernas H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37(10\u201311):1015\u201351.","journal-title":"Xenobiotica"},{"issue":"3-4","key":"1221_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejps.2006.04.015","volume":"29","author":"E Bergman","year":"2006","unstructured":"Bergman E, Forsell P, Tevell A, Persson EM, Hedeland M, Bondesson U, et al. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur J Pharm Sci. 2006;29(3\u20134):205\u201314.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"1221_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/mnfr.201500692","volume":"60","author":"M Zeng","year":"2016","unstructured":"Zeng M, Sun R, Basu S, Ma Y, Ge S, Yin T, et al. Disposition of flavonoids via recycling: direct biliary excretion of enterically or extrahepatically derived flavonoid glucuronides. Mol Nutr Food Res. 2016;60(5):1006\u201319.","journal-title":"Mol Nutr Food Res"},{"issue":"7","key":"1221_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2174\/1568009618666181029153255","volume":"19","author":"R Sun","year":"2019","unstructured":"Sun R, Basu S, Zeng M, Sunsong R, Li L, Ghose R, et al. Xiao-Chai-Hu-Tang (XCHT) intervening irinotecan\u2019s disposition: the potential of XCHT in alleviating irinotecan-induced diarrhea. Curr Cancer Drug Targets. 2019;19(7):551\u201360.","journal-title":"Curr Cancer Drug Targets"},{"issue":"11","key":"1221_CR17","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1021\/acs.jmedchem.0c01720","volume":"64","author":"D Zhang","year":"2021","unstructured":"Zhang D, Wei C, Hop C, Wright MR, Hu M, Lai Y, et al. Intestinal excretion, intestinal recirculation, and renal tubule reabsorption are underappreciated mechanisms that drive the distribution and pharmacokinetic behavior of small molecule drugs. J Med Chem. 2021;64(11):7045\u201359.","journal-title":"J Med Chem"},{"issue":"5","key":"1221_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.647","volume":"8","author":"S Fernandez","year":"2020","unstructured":"Fernandez S, Lenoir C, Samer C, Rollason V. Drug interactions with apixaban: a systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Pharmacol Res Perspect. 2020;8(5):e00647.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"1221_CR19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","volume":"49","author":"S Hanigan","year":"2020","unstructured":"Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. 2020;49(4):636\u201343.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"1221_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/cts.12580","volume":"11","author":"B Bashir","year":"2018","unstructured":"Bashir B, Stickle DF, Chervoneva I, Kraft WK. Drug-drug interaction study of apixaban with cyclosporine and tacrolimus in healthy volunteers. Clin Transl Sci. 2018;11(6):590\u20136.","journal-title":"Clin Transl Sci"},{"issue":"10","key":"1221_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02927-4","volume":"37","author":"JK Sodhi","year":"2020","unstructured":"Sodhi JK, Liu S, Benet LZ. Intestinal efflux transporters P-gp and BCRP are not clinically relevant in apixaban disposition. Pharm Res. 2020;37(10):208.","journal-title":"Pharm Res"},{"issue":"12","key":"1221_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/jps.2600771204","volume":"77","author":"M Hu","year":"1988","unstructured":"Hu M, Amidon GL. Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci. 1988;77(12):1007\u201311.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1221_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1124\/dmd.110.036442","volume":"39","author":"L Wang","year":"2011","unstructured":"Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, et al. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos. 2011;39(2):256\u201364.","journal-title":"Drug Metab Dispos"},{"key":"1221_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jchromb.2016.02.012","volume":"1015-1016","author":"S Basu","year":"2016","unstructured":"Basu S, Zeng M, Yin T, Gao S, Hu M. Development and validation of an UPLC-MS\/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: application to a pharmacokinetic study of irinotecan in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1015\u20131016:34\u201341.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"9","key":"1221_CR25","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1124\/dmd.110.033019","volume":"38","author":"L Kagan","year":"2010","unstructured":"Kagan L, Dreifinger T, Mager DE, Hoffman A. Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. Drug Metab Dispos. 2010;38(9):1560\u20136.","journal-title":"Drug Metab Dispos"},{"key":"1221_CR26","unstructured":"U.S. Food and Drug Administration. Bioanalytical Method Validation: Guidance for Industry. Silver Spring(MD): Center for Drug Evaluation and Research (CDER); 2018. https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed January 13, 2026."},{"issue":"1","key":"1221_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1124\/dmd.108.023143","volume":"37","author":"N Raghavan","year":"2009","unstructured":"Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74\u201381.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1221_CR28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1023\/A:1015906409585","volume":"7","author":"M Hu","year":"1990","unstructured":"Hu M, Borchardt RT. Mechanism of l-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2). Pharm Res. 1990;7(12):1313\u20139.","journal-title":"Pharm Res"},{"issue":"1","key":"1221_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10146","volume":"5","author":"A Kothari","year":"2020","unstructured":"Kothari A, Rajagopalan P. The assembly of integrated rat intestinal-hepatocyte cultures. Bioeng Transl Med. 2020;5(1):e10146.","journal-title":"Bioeng Transl Med"},{"issue":"9","key":"1221_CR30","first-page":"392","volume":"19","author":"KO Haustein","year":"1981","unstructured":"Haustein KO, Fritzsche K. On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent. Int J Clin Pharmacol Ther. 1981;19(9):392\u20135.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"1221_CR31","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1124\/dmd.113.054932","volume":"42","author":"G Englund","year":"2014","unstructured":"Englund G, Lundquist P, Skogastierna C, Johansson J, Hoogstraate J, Afzelius L, et al. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors. Drug Metab Dispos. 2014;42(3):441\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1221_CR32","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s11095-005-2588-5","volume":"22","author":"W Weitschies","year":"2005","unstructured":"Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, et al. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res. 2005;22(5):728\u201335.","journal-title":"Pharm Res"},{"issue":"1","key":"1221_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.207","volume":"4","author":"W Ankrom","year":"2016","unstructured":"Ankrom W, Wood HB, Xu J, Geissler W, Bateman T, Chatterjee MS, et al. Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target. Pharmacol Res Perspect. 2016;4(1):e00207.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"1221_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1248\/bpb.26.199","volume":"26","author":"W Gao","year":"2003","unstructured":"Gao W, Kageyama M, Inoue Y, Tadano J, Fukumoto K, Fukushima K, et al. Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats. Biol Pharm Bull. 2003;26(2):199\u2013204.","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"1221_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/jps.2600740319","volume":"74","author":"I Johno","year":"1985","unstructured":"Johno I, Kitazawa S. Segmental difference and effect of glucose on drug exsorption across the small intestine of rats. J Pharm Sci. 1985;74(3):316\u201320.","journal-title":"J Pharm Sci"},{"issue":"8","key":"1221_CR36","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1124\/dmd.112.045930","volume":"40","author":"R Sane","year":"2012","unstructured":"Sane R, Agarwal S, Elmquist WF. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012;40(8):1612\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"1221_CR37","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","volume":"20","author":"CM Kruijtzer","year":"2002","unstructured":"Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol. 2002;20(13):2943\u201350.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1221_CR38","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1124\/dmd.112.050575","volume":"41","author":"D Zhang","year":"2013","unstructured":"Zhang D, Frost CE, He K, Rodrigues AD, Wang X, Wang L, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos. 2013;41(4):906\u201315.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1221_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006780","volume":"13","author":"MA El-Brolosy","year":"2017","unstructured":"El-Brolosy MA, Stainier DYR. Genetic compensation: a phenomenon in search of mechanisms. PLoS Genet. 2017;13(7):e1006780.","journal-title":"PLoS Genet"},{"issue":"4","key":"1221_CR40","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1124\/dmd.112.050260","volume":"41","author":"D Zhang","year":"2013","unstructured":"Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41(4):827\u201335.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1221_CR41","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","volume":"31","author":"PC Wong","year":"2011","unstructured":"Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478\u201392.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"1221_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11095-004-9004-4","volume":"22","author":"CY Wu","year":"2005","unstructured":"Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport\/absorption\/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11\u201323.","journal-title":"Pharm Res"},{"issue":"12","key":"1221_CR43","doi-asserted-by":"publisher","first-page":"12473","DOI":"10.1021\/acs.jmedchem.5c00056","volume":"68","author":"KM Redeker","year":"2025","unstructured":"Redeker KM, Kirsch N, Boretius S, Tzvetkov M, Brockmoller J. Substrate specificity of the organic cation transporters MATE1 and MATE2K and functional overlap with OCT1 and OCT2. J Med Chem. 2025;68(12):12473\u201392.","journal-title":"J Med Chem"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01221-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01221-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:02:18Z","timestamp":1774465338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01221-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01221-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests. Dr. Ming Hu is a co-founder of Sanarentero LLC. Yiding Hu, Yurong Lai, Xiaofeng\u00a0Zhao, Jia Hao, John Chen are employees of Gilead Sciences Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"70"}}